Figures published by the European Medicines Agency (EMA) relating to centralized procedure activities for human medicines show a significant increase in the number of positive opinions made between 2007 and 2009; however, the majority of approvals are for generic products.
VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.
EMA statistics highlighting centralized-procedure activities for human medicines show a significant increase in positive opinions made between 2007 and 2009.
Capsules that can release their contents at a selected temperature have been developed by researchers in France, and could lead to the development of therapeutic agents that are applied to the skin and triggered locally by rubbing.
Cephalon Buys Mepha; BASi's CEO Retires; and More.
Hoping to prevent the deaths of eight million children over the next decade, Bill and Melinda Gates recently committed $10 billion for child-immunization programs in the world's poorest countries.
3M Drug Delivery Systems Division Vice President Jim Vaughan discusses facility locations and the drug-product inhalation market.
The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.
Sharing too much-or too little-information can have disastrous onsequences.
As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.
FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.
A recent book provides information about formulating biopharmaceuticals that is easy to swallow.
Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.
Regulators and industry move to require inspections of API manufacturing facilities.
When it comes to healthcare rform, we must not overlook investment in innovative technologies.
The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods. This article contain bonus online material.
The vaccine sector is challenging for both R&D and manufacturing because a wide variety of technologies and techniques are required — even the largest companies find it difficult to cover all the relevant areas of expertise — and this drives up development costs and often forces companies into multiple collaborations to obtain the required expertise and technologies.
Eran Gabbai, CEO and President of Do-Coop Technologies, explains the benefits of a new water-based nanotechnology.
The Director General of the European Generic medicines Association (EGA) has reiterated the association?s Vision 2015 plan, which aims to create a globally competitive generic industry, increase patient access to affordable quality medicines and ensure sustainable healthcare in Europe.
Novartis CEO To Step Down; DSM To Close Netherlands Facility; And More.
The Director-General of the European Generic medicines Association has reiterated the group's Vision 2015 plan.
FDA Issues Warning Letter To McNeil Healthcare; Charles River Laboratories Will Suspend Operations At Massachusetts Facility.
The authors sought to improve the productivity of protein synthesis by using a highly active cell-free extract from Escherichia coli and by optimizing buffer conditions and shaking conditions.
The United States Pharmacopeial Convention is recalling USP 33?NF 28.
Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna (Austria).